Early in-hospital aspirin desensitization was feasible and safe in a patient with STEMI and aspirin allergy, allowing timely initiation of guideline-recommended dual antiplatelet therapy.
Case Report (n=1)
Does early in-hospital aspirin desensitization allow safe initiation of dual antiplatelet therapy in a patient with STEMI and aspirin-induced angioedema?
Early in-hospital aspirin desensitization is feasible and safe for patients with aspirin allergy presenting with STEMI, enabling the use of guideline-directed dual antiplatelet therapy.
We report a 47-year-old male presenting with inferior ST-segment elevation myocardial infarction (STEMI) and a history of aspirin-induced angioedema. Despite the challenges of antithrombotic management in the context of aspirin allergy, the patient underwent successful primary percutaneous coronary intervention (PCI), followed by early in-hospital aspirin desensitization. This case highlights the feasibility and safety of early desensitization, allowing timely initiation of guideline-recommended dual antiplatelet therapy in a high risk setting.
Namnoum et al. (Fri,) conducted a case report in ST-segment elevation myocardial infarction (STEMI) and aspirin-induced angioedema (n=1). Early in-hospital aspirin desensitization was evaluated on Feasibility and safety of early desensitization. Early in-hospital aspirin desensitization was feasible and safe in a patient with STEMI and aspirin allergy, allowing timely initiation of guideline-recommended dual antiplatelet therapy.